Covered Stent Market Report: Market Size & Forecast 2026

Covered stents, also known as stent-grafts, are tubular metal scaffolds lined with biocompatible fabric materials such as polytetrafluoroethylene or polyester. They are primarily deployed via endovascular procedures to reinforce weakened blood vessels, seal aneurysms, and restore blood flow while excluding the diseased vessel segment from circulation. The global market spans a wide range of applications across thoracic, abdominal, and peripheral vascular territories, with device designs varying by vessel anatomy and pathology type.

• •Estimated global market size around $1.56 billion in 2025, with projections reaching approximately $2.1 billion by the early 2030s depending on scope and methodology
• •Annual growth rates consistently reported in the 3.9% to 4.6% range across major industry analyses for the 2025-2033 period
• •The broader stents market is valued significantly higher at roughly $14.5 billion in 2025, with covered stents representing a specialized and higher-value segment

Rising prevalence of aortic aneurysms and peripheral artery disease, particularly among aging populations, is a primary factor fueling demand for covered stents. Advancements in minimally invasive endovascular techniques have expanded the eligible patient pool by making procedures accessible to higher-risk surgical candidates. Additionally, improving healthcare infrastructure in emerging markets and growing awareness of vascular disease screening are contributing to earlier diagnosis and intervention rates.

• •Global aging demographic trends increase incidence of degenerative vascular conditions requiring stent-graft intervention
• •Endovascular procedures have largely replaced open surgical repair for many aortic and peripheral indications due to lower morbidity and faster recovery
• •Favorable reimbursement policies in developed markets and expanding insurance coverage in Asia-Pacific and Latin America support procedure volume growth

The covered stent market is typically segmented by product type, including abdominal aortic stent-grafts, thoracic aortic stent-grafts, and peripheral covered stents, each serving distinct anatomical regions and clinical indications. North America commands the largest regional share, with projections indicating the regional market will reach approximately $591 million by 2030. Europe and Asia-Pacific follow as significant markets, with the latter expected to register the fastest growth rates due to rising healthcare expenditure and improving access to advanced vascular interventions.

• •North America leads with steady growth around 3.4% CAGR, supported by advanced healthcare systems, high procedure volumes, and presence of major device manufacturers
• •Asia-Pacific is emerging as the fastest-growing region, driven by improving vascular surgery capabilities, rising chronic disease burden, and expanding hospital infrastructure
• •Abdominal aortic stent-grafts constitute the largest application segment, followed by thoracic aortic and peripheral vascular applications

What are the recent trends and outlook?

Ongoing product development is focused on improving conformability, delivery profile, and biocompatibility to expand treatment options for challenging anatomies such as short necks, tortuous vessels, and arch pathologies. Customized and patient-specific stent-graft solutions, enabled by 3D imaging and printing technologies, represent an emerging trend that could reshape the competitive landscape over the forecast period. While regulatory pathways and pricing pressures in certain markets present challenges, the long-term outlook remains positive as technological innovation and procedural experience continue to drive adoption across new indications and geographic markets.

• •Next-generation devices with thinner profiles, improved flexibility, and bifurcated designs aim to reduce procedure complexity and improve patency rates
• •Off-the-shelf fenestrated and branched stent-grafts are gaining adoption for complex juxtarenal and arch aortic aneurysms, expanding the treatable patient population
• •Increasing emphasis on value-based healthcare is driving demand for clinical evidence demonstrating cost-effectiveness and long-term durability compared to alternative treatment modalities